 | Acceleron Pharma's (XLRN) "Buy" Rating Reiterated at Cowen
www.americanbankingnews.com - October 13 at 9:16 PM |
| Morgan Stanley Lowers Acceleron Pharma (NASDAQ:XLRN) Price Target to $48.00
www.americanbankingnews.com - October 11 at 2:01 PM |
 | One Thing To Remember About The Acceleron Pharma Inc. (NASDAQ:XLRN) Share Price
finance.yahoo.com - October 10 at 6:29 PM |
| Acceleron Pharma Inc (NASDAQ:XLRN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 8 at 6:54 AM |
| Acceleron Pharma Inc (NASDAQ:XLRN) Expected to Post Quarterly Sales of $3.45 Million
www.americanbankingnews.com - October 6 at 2:19 PM |
 | Here’s Why Acceleron Pharma Stock Fell 12% in September
www.fool.com - October 5 at 4:48 PM |
| Analysts Expect Acceleron Pharma Inc (NASDAQ:XLRN) to Post -$0.81 Earnings Per Share
www.americanbankingnews.com - October 4 at 7:47 AM |
| Critical Analysis: Acceleron Pharma (NASDAQ:XLRN) vs. Mymetics (NASDAQ:MYMX)
www.americanbankingnews.com - September 29 at 12:15 AM |
 | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
www.msn.com - September 20 at 12:17 AM |
| Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock.
finance.yahoo.com - September 17 at 12:19 PM |
| This Biotech Just Flopped On A Test; Why Analysts Remain Bullish
finance.yahoo.com - September 17 at 12:19 PM |
 | Biogen, Acceleron terminate drugs after poor trials
www.bizjournals.com - September 17 at 8:15 AM |
 | Acceleron bails on candidate ACE-083; shares down 3% after hours
seekingalpha.com - September 16 at 6:01 PM |
| Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
finance.yahoo.com - September 16 at 6:00 PM |
| Acceleron Pharma stock down 4% after company halts treatment trial
finance.yahoo.com - September 16 at 6:00 PM |
| FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
finance.yahoo.com - September 11 at 6:56 AM |
 | Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation
www.benzinga.com - September 9 at 11:46 AM |
| Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
finance.yahoo.com - September 9 at 11:46 AM |
 | Acceleron Pharma Breaks Below 200-Day Moving Average - Notable for XLRN
www.nasdaq.com - September 5 at 3:38 PM |
| Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?
finance.yahoo.com - August 20 at 11:07 AM |
| Should You Worry About Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Cheque?
finance.yahoo.com - August 20 at 11:07 AM |
| Edited Transcript of XLRN earnings conference call or presentation 5-Aug-19 9:00pm GMT
finance.yahoo.com - August 6 at 11:52 PM |
| Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript
www.fool.com - August 6 at 11:28 AM |
| What You'll Want to Know About Acceleron Pharma's Q2 Update
finance.yahoo.com - August 6 at 9:06 AM |
| What You'll Want to Know About Acceleron Pharma's Q2 Update
www.fool.com - August 6 at 7:46 AM |
 | ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN
www.rttnews.com - August 6 at 4:38 AM |
| Acceleron Pharma EPS misses by $0.11, misses on revenue
seekingalpha.com - August 5 at 11:41 PM |
| Acceleron Pharma Q2 2019 Earnings Preview
seekingalpha.com - August 4 at 10:37 PM |
| Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock?
finance.yahoo.com - July 15 at 6:59 PM |
| Acceleron Pharma Inc. Common Stock Historical Stock Prices
www.nasdaq.com - July 8 at 6:48 PM |
| Acceleron Pharma Inc. Institutional Ownership
www.nasdaq.com - July 8 at 6:48 PM |
| Acceleron completes enrollment in mid-stage study of sotatercept in PAH
seekingalpha.com - June 26 at 8:26 AM |
| Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis
finance.yahoo.com - June 15 at 12:26 AM |
| Acceleron co-founder bids adieu
seekingalpha.com - June 10 at 8:32 AM |
| Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis
finance.yahoo.com - June 10 at 8:32 AM |
| Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
finance.yahoo.com - June 6 at 7:07 PM |
| Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
finance.yahoo.com - June 6 at 7:07 PM |
| BIO 2019: Gene therapy surging, but challenges remain
www.bizjournals.com - June 5 at 6:58 PM |
| Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
finance.yahoo.com - June 4 at 8:24 AM |
| The Investment Thesis On Acceleron Pharma
seekingalpha.com - May 28 at 8:19 AM |
| Acceleron to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 14 at 8:40 AM |
| Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT
finance.yahoo.com - May 10 at 6:55 PM |
| Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:23 AM |
| Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 8:23 AM |
| Acceleron Pharma Inc (XLRN) Q1 2019 Earnings Call Transcript
www.fool.com - May 9 at 11:13 PM |
 | Acceleron Reports First Quarter 2019 Operating and Financial Results
www.businesswire.com - May 9 at 7:45 PM |
| Acceleron Pharma misses by $0.10, misses on revenue
seekingalpha.com - May 9 at 7:45 PM |
| Acceleron Pharma Q1 2019 Earnings Preview
seekingalpha.com - May 8 at 7:38 PM |
| Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
finance.yahoo.com - May 6 at 8:21 AM |
| Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019
finance.yahoo.com - May 1 at 8:17 AM |
